{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"93.3"},{"groupId":"OG001","spread":"1.0","value":"93.3"}]}],"title":"Pre-cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1","value":"91.6"},{"groupId":"OG001","spread":"1.1","value":"91.6"}]}],"title":"Pree-cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1","value":"98.0"},{"groupId":"OG001","spread":"1.3","value":"97.6"}]}],"title":"30 weeks post cycle 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"184"}],"units":"Participants"}],"description":"Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-En TOI). The FACT-En TOI is a scale for assessing general QOL of endometrial cancer patients. The FACT-En TOI score ranges 0-120 with a large score suggesting better QOL. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life.","dispersionType":"Standard Error","groups":[{"description":"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1.\n\nCarboplatin: Given IV\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Regimen I - Uterine and Non-Uterine Subjects"},{"description":"Patients receive ifosfamide IV over 1 hour on days 1-3 followed by paclitaxel as in Arm I.\n\nIfosfamide: Given IV\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Regimen II - Uterine and Non-Uterine Subjects"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Provided baseline and ≥ 1 follow-up assessments","reportingStatus":"POSTED","timeFrame":"Prior to cycle 3, Prior to cycle 6, 30 weeks post cycle 1.","title":"Patient Reported Quality of Life (QOL) - Post Baseline","type":"SECONDARY","unitOfMeasure":"units on a scale (time point)"}